294 related articles for article (PubMed ID: 30312931)
1. l,8-Naphthalimide based DNA intercalators and anticancer agents. A systematic review from 2007 to 2017.
Tomczyk MD; Walczak KZ
Eur J Med Chem; 2018 Nov; 159():393-422. PubMed ID: 30312931
[TBL] [Abstract][Full Text] [Related]
2. Anticancer Activity and Topoisomerase II Inhibition of Naphthalimides with ω-Hydroxylalkylamine Side-Chains of Different Lengths.
Tomczyk MD; Byczek-Wyrostek A; Strama K; Wawszków M; Kasprzycki P; Walczak KZ
Med Chem; 2019; 15(5):550-560. PubMed ID: 30207241
[TBL] [Abstract][Full Text] [Related]
3. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
Wang X; Chen Z; Tong L; Tan S; Zhou W; Peng T; Han K; Ding J; Xie H; Xu Y
Eur J Med Chem; 2013 Jul; 65():477-86. PubMed ID: 23770449
[TBL] [Abstract][Full Text] [Related]
4. Design of DNA Intercalators Based on 4-Carboranyl-1,8-Naphthalimides: Investigation of Their DNA-Binding Ability and Anticancer Activity.
Rykowski S; Gurda-Woźna D; Orlicka-Płocka M; Fedoruk-Wyszomirska A; Giel-Pietraszuk M; Wyszko E; Kowalczyk A; Stączek P; Biniek-Antosiak K; Rypniewski W; Olejniczak AB
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562989
[TBL] [Abstract][Full Text] [Related]
5. 1,8-Naphthalimide: A Potent DNA Intercalator and Target for Cancer Therapy.
Tandon R; Luxami V; Kaur H; Tandon N; Paul K
Chem Rec; 2017 Oct; 17(10):956-993. PubMed ID: 28375569
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of novel ellipticines as potential anti-cancer agents.
Deane FM; O'Sullivan EC; Maguire AR; Gilbert J; Sakoff JA; McCluskey A; McCarthy FO
Org Biomol Chem; 2013 Feb; 11(8):1334-44. PubMed ID: 23314103
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of novel C4-benzazole naphthalimide derivatives with potent anti-tumor properties against murine melanoma.
Lu YT; Chen TL; Chang KS; Chang CM; Wei TY; Liu JW; Hsiao CA; Shih TL
Bioorg Med Chem; 2017 Jan; 25(2):789-794. PubMed ID: 27939348
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in silico assessment of DNA interaction, topoisomerase I and II inhibition properties of chrysosplenetin.
Şöhretoğlu D; Barut B; Sari S; Özel A; Arroo R
Int J Biol Macromol; 2020 Nov; 163():1053-1059. PubMed ID: 32673727
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of naphthalimide-phenanthro[9,10-d]imidazole derivatives: In vitro evaluation, binding interaction with DNA and topoisomerase inhibition.
Singh I; Luxami V; Paul K
Bioorg Chem; 2020 Mar; 96():103631. PubMed ID: 32036164
[TBL] [Abstract][Full Text] [Related]
10. Design and Discovery of Novel Quinoxaline Derivatives as Dual DNA Intercalators and Topoisomerase II Inhibitors.
Eissa IH; El-Naggar AM; El-Sattar NEAA; Youssef ASA
Anticancer Agents Med Chem; 2018; 18(2):195-209. PubMed ID: 28699490
[TBL] [Abstract][Full Text] [Related]
11. 3-chloromethylene-6-fluorothiochroman-4-one, A novel DNA Topoisomerase poison.
Wang Y; Chen J; Shen R; Yang C; Ma Z; Liu Y
Pak J Pharm Sci; 2016 Nov; 29(6 Suppl):2377-2383. PubMed ID: 28167481
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and antitumor activity of non-camptothecin topoisomerase I inhibitors.
Zhang C; Li S; Ji L; Liu S; Li Z; Li S; Meng X
Bioorg Med Chem Lett; 2015 Oct; 25(20):4693-6. PubMed ID: 26384290
[TBL] [Abstract][Full Text] [Related]
14. Tacrine derivatives as dual topoisomerase I and II catalytic inhibitors.
Janočková J; Plšíková J; Koval' J; Jendželovský R; Mikeš J; Kašpárková J; Brabec V; Hamuľaková S; Fedoročko P; Kožurková M
Bioorg Chem; 2015 Apr; 59():168-76. PubMed ID: 25827869
[TBL] [Abstract][Full Text] [Related]
15. Pyrroloquinolinone-based dual topoisomerase I/II inhibitor.
Dalla Via L; Marzaro G; Ferrarese A; Gia O; Chilin A
Eur J Med Chem; 2014 Apr; 77():103-9. PubMed ID: 24631729
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Evaluation of Novel 3-Carboranyl-1,8-Naphthalimide Derivatives as Potential Anticancer Agents.
Rykowski S; Gurda-Woźna D; Orlicka-Płocka M; Fedoruk-Wyszomirska A; Giel-Pietraszuk M; Wyszko E; Kowalczyk A; Stączek P; Bak A; Kiliszek A; Rypniewski W; Olejniczak AB
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803403
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of Triphenylethylene-Naphthalimide Conjugates as topoisomerase-IIα inhibitor and HSA binder.
Rani S; Luxami V; Paul K
ChemMedChem; 2021 Jun; 16(11):1821-1831. PubMed ID: 33725393
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
[TBL] [Abstract][Full Text] [Related]
19. A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study.
Karki R; Jun KY; Kadayat TM; Shin S; Thapa Magar TB; Bist G; Shrestha A; Na Y; Kwon Y; Lee ES
Eur J Med Chem; 2016 May; 113():228-45. PubMed ID: 26945111
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and anticancer activities of 6-amino amonafide derivatives.
Norton JT; Witschi MA; Luong L; Kawamura A; Ghosh S; Stack MS; Sim E; Avram MJ; Appella DH; Huang S
Anticancer Drugs; 2008 Jan; 19(1):23-36. PubMed ID: 18043127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
